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1. Introduction 
Carnitine acetyltransferase (CAT) (EC 2.3.1.7) 
is an enzyme catalyzing the reversible transfer of an 
acetyl group from acetyl-CoA to camitine. This en- 
zyme is primarily located in the membranous part of 
the mitochondria [ 1 ] . The activity of the enzyme has 
been found to be high in heart, testis, brown adipose 
tissue and skeletal muscle but low in liver [2]. Fasting 
increases the activity of the liver enzyme [3]. 
In spite of this substantial ibformation about the 
behaviour and location of CAT, its physiological 
function is uncertain. Some investigators have propo- 
sed a role as an acetyl carrier throughout the cell [4] 
but this has been disputed by many authors who have 
suggested an acetyl group buffering function for CAT 
[5] . In either case, through acetyl group and camitine 
metabolism, it could influence both lipid and carbohy- 
drate metabolism [6]. 
Clofibrate (ethyl-&p-chlorophenoxyisobutyrate) 
is a well-known drug decreasing the concentrations of
plasma lipids, especially that of triglycerides [7]. It 
affects the hepatic metabolism of free fatty acids and 
triglycerides [8] and changes the activity of several 
enzymes [9,10]. Because CAT may have a central role 
in lipid metabolism, we have now studied the effect 
of clofibrate treatment on CAT activity in some rat 
tissues. Two different doses of clofibrate were adminis- 
tered, and the resulting changes in CAT activity were 
compared with the effect of thyroxine. 
2. Materials and methods 
Two series of experiments were conducted: in the 
North-Holland Publishing Company - Amsterdam 
first, 30 or 200 mg clofibrate/day/kg body weight was 
administered subcutaneously to male Wistar ats 
weighing 180-250 g for 14 successive days. Body 
weights were recorded and the doses of the drug were 
corrected twice during treatment. In the second series 
50 mg clofibrate or 0.1 mg Na-L-thyroxine/day/ 
animal was given subcutaneously to rats weighing 
270-310 g for 9 successive days. Control animals 
were subjected to the same treatment except that 
clofibrate and thyroxine were omitted. The rats in 
both the experimental nd control groups howed a 
steady increase in body weight during treatment. No 
fasting preceded the experiments. 
CAT was extracted from heart and skeletal muscle 
three times with 0.1 M phosphate buffer, pH 8.0, 
containing 0.1% deoxycholate and 10 mM EDTA 
[2]. In the liver the activity of CAT was so low that 
it could be accurately measured only from isolated 
mitochondria. The mitochondria were isolated in 0.25 
M sucrose with 1 mM EDTA and 5 mM Tris, pH 7.4, 
and CAT was extracted from them as described above. 
The activity of CAT was measured with a coupled 
assay using acetyl-D,Lcarnitine as substrate [2]. The 
reaction temperature was 25°C. The activity of mi- 
tochondrial qlycerophosphate dehydrogenase was 
measured polarographically [ 1 l] . Protein was deter- 
mined by the biuret method [ 111. 
The results are given as means k SEM. Statistical 
significance was calculated with Student’s t-test. 
Clofibrate was a generous gift from Orion Pharma- 
ceutical Co., Helsinki, Finland. Na-Lthyroxine was 
from Fluka AG, Buchs, Switzerland. Acetyl-D,L 
carnitine, coenzymes and enzymes needed were ob- 
tained from Boehringer und Soehne GmbH, Mann- 
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heim, Germany. 
3. Results and discussion 
Two doses of clotibrate were used in the first se- 
ries of experiments. The larger dose (200 mglkg 
body wt. daily s.c.) has previously been found to have 
a near maximal effect on the hepatic enzyme activi- 
ties which we have studied (K&Gnen, to be published) 
and the smaller dose (30 mg/kg body wt. daily) has a 
maximal effect on plasma triglyceride level in rats when 
administered daily subcutaneously (Ktiihiinen, to be 
published). In addition, the smaller dose is about the 
same as the therapeutic dose in human subjects cal- 
culated on weight basis. 
The larger dose of clofibrate induced an almost en 
fold increase in the activity of CAT in rat liver mi- 
tochondria (table 1). The smaller dose had no signi- 
ficant effect. Thus there was a discrepancy between 
the lipid lowering effect of clofibrate and the induc- 
tion of enzyme activity. 
Daae and Aas found in rat liver a rise in the activity 
of carnitine palmityltransferase to 260% of the activi- 
ty of control livers as a result of clofibrate treatment 
[ 121. Their dose of clofibrate (0.30% in the diet) is 
not easily convertible to our own doses. However, 
assuming an average consumption of 10 g food/day, 
the dose they used corresponds to 150-200 mg 
Table 1 
Effect of clofibrate treatment on the activity of carnitine 
acetyltransferase of rat liver mitochondria, heart and 
muscle tissue 
Liver mito- Heart Muscle 
chondria bmoles/min/ 
(pmoles/min/ g wet. wt.1 
g protein) 
Control 10.83 i 2.41 13.67 f 0.91 3.39 f 0.44 
Clofibrate 30 
mg/kg/day 13.87 f 1.81 15.46 f 1.56 3.14 f 0.20 
Clotibrate 200 
mg/kg/day 98.68 f 9.59* 19.91 f 1.10-3.14 f 0.40 
Six rats in each group. Figures are means f SEM. Significance 
of the values in comparison to the control group. 
* p = < 0.001. 
**p = < 0.01. 
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clotibrate/kg daily, which is close to the larger dose 
we used. Thus, the clofibrate-induced increase in the 
CAT activity seems to be much greater than the rise 
in the activity of carnitine palmityltransferase. 
The clofibrate-induced rise in CAT activity is 
probably responsible for the great increase in the 
oxygen consumption after addition of carnitine to 
mitochondrial suspension using octanoate as substrate 
[ 131. A possible change in the activity of the third 
enzyme known to use carnitine as a substrate, carni- 
tine octanoyltransferase [ 141, is probably not in- 
volved in this effect, because the oxidation of short 
chain fatty acids in liver preparations of normal rats 
is not dependent on the presence of camitine [ 151. 
In skeletal muscle we found no increase in CAT 
activity after clofibrate treatment (table 1). The ac- 
tivity in heart muscle was increased 45% by the larger 
dose. As with liver mitchondria the smaller dose did 
not cause any significant rise in heart muscle CAT ac- 
tivity. 
Some effects of clofibrate have been suggested to
be mediated by thyroxine [lo] , which is displaced 
from its binding sites in plasma proteins by clofibrate 
[ 161. For example the effects of thyroxine and clofi- 
brate on the activity of mitochondrial qlycerophos- 
phate dehydrogenase activity in rat liver are similar 
and very large [IO] . Therefore, it was interesting to 
know, whether thyroxine and clofibrate treatments 
had similar effect on mitochondrial CAT activity, 
too. Both treatments markedly increased the mitchon- 
drill cw-glycerophosphate dehydrogenase activity, but 
only clotibrate had an effect on the activity of CAT 
(table 2). This result confirms the view that all effects 
of clofibrate are not mediated by thyroxine. 
The mechanism by which clofibrate increases CAT 
activity is unsolved. Most probably it induces de novo 
synthesis of the enzyme protein, but this remains to 
be elucidated. The activity of the enzyme was previ- 
ously believed to be located almost exclusively in the 
membranous part of mitochondria, but a more recent 
report indicates that in the rat liver a considerable 
parIt of the activity is found in peroxisomes and in a 
lipid-rich membranous fraction [ 171. Clofibrate treat- 
ment has been found to increase the content of 
peroxisomes in the liver [ 181 . It also increasesthe 
activity of the peroxisomal marker enzyme, catalase 
[ 191. The method which we used to isolate mitochon- 
dria does not separate peroxisomes from the rnitochon- 
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Table 2 
Effect of clofibrate and thyroxine treatment on the activity 
of carnitine acetyltransferase and cr-glycerophosphate 
dehydrogenase in rat liver mitochondria 
fully acknowledged. This work was supported by a 
grant from The Finnish Cultural Foundation. 
Camltine acetyl- WGlycerophosphate 
transferase dehydrogenase 
@moles/min/g (Cratoms O/min/g 
protein) protein) 
Control 
Thyroxine 
0.1 mgjday 
Clotibrate 
50 mglday 
7.11 f 1.40 2.60 f 0.16 
11.47 f 3.24 27.44 f 3.92** 
10274 i 20.00* 15.99 i 1.65** 
Five rats in each group. Figures are means f iSEM. Signifi- 
cance of the values in comparison to the control group. 
* p = < 0.01. 
**p = < 0.001. 
drial fraction. Thus it is possible that at least part of 
the increase in CAT activity occurs in peroxisomes. 
The physiological significance of CAT is open. 
Thus it is too early to speculate about the meaning 
of the clofibrate-induced increase in its activity. It is 
hardly important in the hypolipidaemic action of clo- 
fibrate, because therapeutic doses which lower lipid 
concentrations have no effect on the CAT activity. 
However, the change produced by larger doses of clofi- 
brate must have a profound effect on the metabolism 
of acetyl groups and camitine in the liver. Therefore 
the clofibrate-treated rat offers a model in which the 
metabolic role of hepatic CAT can be tested. 
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